Patents by Inventor Jackie Papkoff
Jackie Papkoff has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11969446Abstract: The disclosure relates generally to bacterial strains of the genus Christensenella, e.g., Christensenella sp. P152-H6d bacterial strains, and compositions comprising such bacterial strains. The disclosure further relates to methods of using such bacterial strains and compositions for preventing or treating a disorder, e.g., an inflammatory disorder, a gastrointestinal disorder, a metabolic disorder, and/or dysbiosis.Type: GrantFiled: August 28, 2020Date of Patent: April 30, 2024Assignee: XBIOME INC.Inventors: Peyman Akbari, Ali Akin, Rounak Feigelman, Wayne Herber, Jason Hudak, Jun Ma, Jackie Papkoff, Lauren Wong
-
Publication number: 20230081756Abstract: The disclosure relates generally to bacterial strains of the genus Butyricimonas, e.g., Butyricimonas faecihominis bacterial strains, and compositions, e.g., pharmaceutical compositions, comprising such strains. The disclosure further relates to methods of using such strains and compositions for preventing or treating a disorder, e.g., a cancer, when administered to a subject in need thereof.Type: ApplicationFiled: December 31, 2020Publication date: March 16, 2023Inventors: Jackie PAPKOFF, Jun MA, Jason HUDAK, Linh NGUYEN
-
Publication number: 20220409675Abstract: The disclosure relates generally to bacterial strains of the genus Anaerostipes, e.g., Anaerostipes rhamnosivorans bacterial strains, and compositions, e.g., pharmaceutical compositions, comprising such bacterial strains. The disclosure further relates to method of using such bacterial strains and compositions for preventing or treating a disorder, e.g., an inflammatory disorder, a gastrointestinal disorder, a metabolic disorder, and/or dysbiosis when administered to a subject in need thereof.Type: ApplicationFiled: November 20, 2020Publication date: December 29, 2022Applicant: XBIOME INC.Inventors: Jason HUDAK, Jun MA, Jackie PAPKOFF
-
Publication number: 20220339212Abstract: The disclosure relates generally to bacterial strains of the genus Christensenella, e.g., Christensenella sp. P152-H6d bacterial strains, and compositions comprising such bacterial strains. The disclosure further relates to methods of using such bacterial strains and compositions for preventing or treating a disorder, e.g, an inflammatory disorder, a gastrointestinal disorder, a metabolic disorder, and/or dysbiosis.Type: ApplicationFiled: August 28, 2020Publication date: October 27, 2022Inventors: Peyman AKBARI, Ali AKIN, Rounak FEIGELMAN, Jason HUDAK, Jun MA, Jackie PAPKOFF, Lauren WONG, Wayne HERBER
-
Publication number: 20210060090Abstract: The disclosure relates generally to bacterial strains of the genus Christensenella, e.g., Christensenella sp. P152-H6d bacterial strains, and compositions comprising such bacterial strains. The disclosure further relates to methods of using such bacterial strains and compositions for preventing or treating a disorder, e.g., an inflammatory disorder, a gastrointestinal disorder, a metabolic disorder, and/or dysbiosis.Type: ApplicationFiled: August 28, 2020Publication date: March 4, 2021Applicants: Assembly Biosciences, Inc., Assembly Biosciences, Inc.Inventors: Peyman Akbari, Ali Akin, Rounak Feigelman, Wayne Herber, Jason Hudak, Jun Ma, Jackie Papkoff, Lauren Wong
-
Publication number: 20200215129Abstract: The disclosure relates generally to bacterial strains and bacterial strain mixtures, e.g., Eubacterium, Bacteroides, and Roseburia bacterial strains and mixtures thereof. The disclosure further relates to methods of using bacterial strains and bacterial strain mixtures for treating a gastrointestinal disorder, e.g., ulcerative colitis, an inflammatory disorder, and/or dysbiosis.Type: ApplicationFiled: September 13, 2019Publication date: July 9, 2020Inventors: Jackie Papkoff, Jun Ma
-
Publication number: 20150175701Abstract: Isolated antibodies and antigen binding fragments thereof directed against Ovr110 which is expressed by head and neck, ovarian, endometrial, kidney, pancreatic, lung or breast cancer are provided. Also provided are cells and methods for their production as well as methods for their use in killing an Ovr110-expressing cancer cells and alleviating or treating an Ovr110-expressing cancer in a mammal. The anti-Ovr110 antibodies modulate Ovr110 function or internalize upon binding to Ovr110 expressed by mammalian cells in vitro and in vivo. Compositions comprising an anti-Ovr110 antibody and a carrier as well as articles of manufacture or kits thereof are also provided. In addition, isolated nucleic acids encoding an anti-Ovr110 antibody, expression vectors containing the isolated nucleic acids, and host cells containing the vectors are provided.Type: ApplicationFiled: December 4, 2014Publication date: June 25, 2015Applicant: diaDexus, Inc.Inventors: Jackie Papkoff, Gundo Diedrich, Shu-Hui Liu, Agnes Nowakowski
-
Patent number: 8906369Abstract: Isolated antibodies and antigen binding fragments thereof directed against Ovr110 which is expressed by head and neck, ovarian, endometrial, kidney, pancreatic, lung or breast cancer are provided. Also provided are cells and methods for their production as well as methods for their use in killing an Ovr110-expressing cancer cells and alleviating or treating an Ovr110-expressing cancer in a mammal. The anti-Ovr110 antibodies modulate Ovr110 function or internalize upon binding to Ovr110 expressed by mammalian cells in vitro and in vivo. Compositions comprising an anti-Ovr110 antibody and a carrier as well as articles of manufacture or kits thereof are also provided. In addition, isolated nucleic acids encoding an anti-Ovr110 antibody, expression vectors containing the isolated nucleic acids, and host cells containing the vectors are provided.Type: GrantFiled: April 24, 2013Date of Patent: December 9, 2014Assignee: diaDexus, Inc.Inventors: Jackie Papkoff, Gundo Diedrich, Shu-Hui Liu, Agnes Nowakowski
-
Publication number: 20130232589Abstract: Isolated antibodies and antigen binding fragments thereof directed against Ovr110 which is expressed by head and neck, ovarian, endometrial, kidney, pancreatic, lung or breast cancer are provided. Also provided are cells and methods for their production as well as methods for their use in killing an Ovr110-expressing cancer cells and alleviating or treating an Ovr110-expressing cancer in a mammal. The anti-Ovr110 antibodies modulate Ovr110 function or internalize upon binding to Ovr110 expressed by mammalian cells in vitro and in vivo. Compositions comprising an anti-Ovr110 antibody and a carrier as well as articles of manufacture or kits thereof are also provided. In addition, isolated nucleic acids encoding an anti-Ovr110 antibody, expression vectors containing the isolated nucleic acids, and host cells containing the vectors are provided.Type: ApplicationFiled: April 24, 2013Publication date: September 5, 2013Applicant: diaDexus, Inc.Inventors: Jackie Papkoff, Gundo Diedrich, Shu-Hui Liu, Agnes Nowakowski
-
Patent number: 8444971Abstract: Isolated antibodies and antigen binding fragments thereof directed against Ovr110 which is expressed by head and neck, ovarian, endometrial, kidney, pancreatic, lung or breast cancer are provided. Also provided are cells and methods for their production as well as methods for their use in killing an Ovr110-expressing cancer cells and alleviating or treating an Ovr110-expressing cancer in a mammal. The anti-Ovr110 antibodies modulate Ovr110 function or internalize upon binding to Ovr110 expressed by mammalian cells in vitro and in vivo. Compositions comprising an anti-Ovr110 antibody and a carrier as well as articles of manufacture or kits thereof are also provided. In addition, isolated nucleic acids encoding an anti-Ovr110 antibody, expression vectors containing the isolated nucleic acids, and host cells containing the vectors are provided.Type: GrantFiled: November 27, 2007Date of Patent: May 21, 2013Assignee: Diadexus, Inc.Inventors: Jackie Papkoff, Gundo Diedrich, Shu-Hui Liu, Agnes Nowakowski
-
Patent number: 8354508Abstract: The invention provides isolated anti-Pro115 antibodies that bind to Pro115. The invention also encompasses compositions comprising an anti-Pro115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro115 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro115 antibodies. The invention encompasses a method of producing the anti-Pro115 antibodies. Other aspects of the invention are a method of killing an Pro115-expressing cancer cell, comprising contacting the cancer cell with an anti-Pro115 antibody and a method of alleviating or treating an Pro115-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro115 antibody to the mammal.Type: GrantFiled: July 20, 2007Date of Patent: January 15, 2013Assignee: Diadexus, Inc.Inventors: Gundo Diedrich, Paul Levi Miller, Jackie Papkoff, Astrid Strelow
-
Publication number: 20120263647Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Pro104) antibodies that bind to Pro104 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro104 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro104 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro104 antibodies. The invention encompasses a method of producing the anti-Pro104 antibodies. Other aspects of the invention are a method of killing a Pro104-expressing cancer cell, comprising contacting the cancer cell with an anti-Pro104 antibody and a method of alleviating or treating a Pro104-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro104 antibody to the mammal.Type: ApplicationFiled: December 16, 2011Publication date: October 18, 2012Applicant: diaDexus, Inc.Inventors: Jackie Papkoff, Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon, Muriel Kmet, Jianwen Tang
-
Patent number: 8287867Abstract: The invention encompasses a method of inhibiting growth of tumor cells in vivo, comprising contacting the cells with an anti-Ovr115 antibody, or antigen binding fragment thereof. This invention also encompasses a method of alleviating an Ovr115-expressing cancer in a mammal, comprising administering a therapeutically effective amount of an anti-Ovr115 antibody, or antigen binding fragment thereof, to the mammal.Type: GrantFiled: February 20, 2008Date of Patent: October 16, 2012Assignee: Diadexus, Inc.Inventor: Jackie Papkoff
-
Patent number: 8080650Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Pro104) antibodies that bind to Pro104 on a mammalian cell in vivo. The invention also encompasses compositions comprising an anti-Pro104 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro104 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro104 antibodies. The invention encompasses a method of producing the anti-Pro104 antibodies. Other aspects of the invention are a method of killing a Pro104-expressing cancer cell, comprising contacting the cancer cell with an anti-Pro104 antibody and a method of alleviating or treating a Pro104-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro104 antibody to the mammal.Type: GrantFiled: January 15, 2009Date of Patent: December 20, 2011Assignee: diaDexus, Inc.Inventors: Jackie Papkoff, Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon, Muriel Kmet, Jianwen Tang
-
Patent number: 7964195Abstract: The invention provides isolated anti-head and neck, ovarian, pancreatic, lung, endometrial or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr110 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr110 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr110 antibodies. The invention encompasses a method of producing the anti-Ovr110 antibodies. Other aspects of the invention are a method of killing an Ovr110-expressing cancer cell by contacting the cancer cell with an anti-Ovr110 antibody and a method of alleviating or treating an Ovr110-expressing cancer in a mammal by administering a therapeutically effective amount of the anti-Ovr110 antibody to the mammal.Type: GrantFiled: January 9, 2006Date of Patent: June 21, 2011Assignee: Diadexus, Inc.Inventors: Jackie Papkoff, Kenneth R. Shroyer
-
Publication number: 20100209438Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr110 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr110 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr110 antibodies. The invention encompasses a method of producing the anti-Ovr110 antibodies. Other aspects of the invention are a method of killing an Ovr110-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr110 antibody and a method of alleviating or treating an Ovr110-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr110 antibody to the mammal.Type: ApplicationFiled: October 9, 2009Publication date: August 19, 2010Inventors: Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon, Jackie Papkoff
-
Publication number: 20100150907Abstract: The invention provides isolated anti-Pro115 antibodies that bind to Pro115. The invention also encompasses compositions comprising an anti-Pro115 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Pro115 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Pro115 antibodies. The invention encompasses a method of producing the anti-Pro115 antibodies. Other aspects of the invention are a method of killing an Pro115-expressing cancer cell, comprising contacting the cancer cell with an anti-Pro115 antibody and a method of alleviating or treating an Pro115-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Pro115 antibody to the mammal.Type: ApplicationFiled: July 20, 2007Publication date: June 17, 2010Applicant: DIADEXUS, INC.Inventors: Gundo Diedrich, Paul Levi Miller, Jackie Papkoff, Astrid Strelow
-
Publication number: 20100143348Abstract: The invention encompasses a method of inhibiting growth of tumor cells in vivo, comprising contacting the cells with an anti-Ovr1 15 antibody, or antigen binding fragment thereof. This invention also encompasses a method of alleviating an Ovr1 15-expressing cancer in a mammal, comprising administering a therapeutically effective amount of an anti-Ovr1 15 antibody, or antigen binding fragment thereof, to the mammal.Type: ApplicationFiled: February 20, 2008Publication date: June 10, 2010Inventor: Jackie Papkoff
-
Publication number: 20100136009Abstract: Isolated antibodies and antigen binding fragments thereof directed against Ovrl 10 which is expressed by head and neck, ovarian, endometrial, kidney, pancreatic, lung or breast cancer are provided. Also provided are cells and methods for their production as well as methods for their use in killing an Ovrl 10-expressing cancer cells and alleviating or treating an Ovrl 10-expressing cancer in a mammal. The anti-Ovrl 10 antibodies modulate Ovrl 10 function or internalize upon binding to Ovrl 10 expressed by mammalian cells in vitro and in vivo. Compositions comprising an anti-Ovrl 10 antibody and a carrier as well as articles of manufacture or kits thereof are also provided. In addition, isolated nucleic acids encoding an anti-Ovrl 10 antibody, expression vectors containing the isolated nucleic acids, and host cells containing the vectors are provided.Type: ApplicationFiled: November 27, 2007Publication date: June 3, 2010Inventors: Jackie Papkoff, Gundo Diedrich, Shu-Hui Liu, Agnes Nowakowski
-
Patent number: 7619068Abstract: The invention provides isolated anti-ovarian, pancreatic, lung or breast cancer antigen (Ovr110) antibodies that internalize upon binding to Ovr110 on a mammalian in vivo. The invention also encompasses compositions comprising an anti-Ovr110 antibody and a carrier. These compositions can be provided in an article of manufacture or a kit. Another aspect of the invention is an isolated nucleic acid encoding an anti-Ovr110 antibody, as well as an expression vector comprising the isolated nucleic acid. Also provided are cells that produce the anti-Ovr110 antibodies. The invention encompasses a method of producing the anti-Ovr110 antibodies. Other aspects of the invention are a method of killing an Ovr110-expressing cancer cell, comprising contacting the cancer cell with an anti-Ovr110 antibody and a method of alleviating or treating an Ovr110-expressing cancer in a mammal, comprising administering a therapeutically effective amount of the anti-Ovr110 antibody to the mammal.Type: GrantFiled: May 10, 2004Date of Patent: November 17, 2009Assignee: diaDexus, Inc.Inventors: Glenn Pilkington, Gilbert-Andre Keller, Wenlu Li, Laura Corral, Iris Simon, Jackie Papkoff